Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News 22nd Century Group Inc XXII

22nd Century Group, Inc. is an agricultural biotechnology company. The Company is focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science. Additionally, the Company provide contract manufacturing services for conventional combustible tobacco products for third-party brands. The Company operates through a single segment named Tobacco... see more

Recent & Breaking News (NDAQ:XXII)

Dramatic Surge in Very Low Nicotine Tobacco Clinical Trials and Science

Business Wire May 31, 2017

Research Reports Initiation on Biotech Stocks -- Alcobra, Cerus, 22nd Century, and Moleculin Biotech

PR Newswire April 3, 2017

The Growth of Legal Cannabis in Approved States

PR Newswire March 28, 2017

Recent Data Projects Growth in the Legal Cannabis Market

PR Newswire March 22, 2017

The Data Surrounding the Legal Cannabis Markets

PR Newswire March 17, 2017

Technical Reports on Biotech Stocks -- Progenics Pharma, Intrexon, Synthetics Biologics, and 22nd Century

PR Newswire February 9, 2017

Cannabis Stocks Positioning to Regain Momentum in 2017

PR Newswire January 12, 2017

FDA Provides Positive and Encouraging Feedback for 22nd Century’s Very Low Nicotine MRTPA Filings

Business Wire January 5, 2017

How These Biotech Stocks are Faring? -- Inovio Pharma, 22nd Century, Omeros, and Cerulean Pharma

PR Newswire December 21, 2016

22nd Century Group Announces Major Scientific Collaboration with University of Virginia

Business Wire December 20, 2016

Rising Global Demand for Cannabis Products and Grow Equipment Continues to Drive Legal Marijuana Opportunity

PR Newswire December 6, 2016

22nd Century to Present Overview of Company’s Medical Marijuana and Industrial Hemp Initiatives at LD Micro Investor Conference

Business Wire December 5, 2016

Biotech Stocks Under Scanner -- PDL BioPharma, Intrexon, 22nd Century, and Marinus Pharma

PR Newswire November 17, 2016

22nd Century Group Files 2016 Third Quarter Report and Announces Conference Call to Provide Business Update

Business Wire November 8, 2016

Mandating a Reduction in the Nicotine Content of Cigarettes Would Likely Decrease Both the Rate and Prevalence of Smoking

Business Wire November 2, 2016

Former Santa Fe Natural Tobacco Company Executive Joins 22nd Century

Business Wire October 26, 2016

22nd Century’s Very Low Nicotine Cigarettes Significantly Reduce Withdrawal and Craving Symptoms in Vulnerable Population Groups

Business Wire October 20, 2016

22nd Century Group Announces Closing of $11.4 Million Above-Market Registered Direct Offering

Business Wire October 19, 2016

22nd Century Group Announces Above-Market Offering for $11.4 Million

Business Wire October 14, 2016

22nd Century Very Low Nicotine Cigarettes Could Reduce U.S. Smoking Rates by More than 75%

Business Wire October 13, 2016